Europe accelerates AI drug discovery as DeepMind spinoff targets trials this year

Quick Summary:

Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups race to turn algorithmic magic into actual treatments.

"We’ll hopefully have some AI-designed drugs in clinical trials by the end of the year,” the firm’s Nobel Prize-winning CEO Demis Hassabis told a panel at the World Economic Forum in Davos this week."That’s the plan.”   The potential of AI-powered drug discovery is huge.

Still, AI’s real power lies in that critical first phase: zeroing in on targets that might’ve otherwise slipped through the cracks, saving researchers time and possibly even unlocking new treatments.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Siôn Geschwindt

Category: Technology

Markets: NetherlandsSouth Africa

Topics: Deep tech Next Featured Insider Artificial Intelligence

Source Website Secure: Yes (HTTPS)

News Sentiment: Positive

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-01-21 @ 15:48:44 (1 days ago)

News Timezone: GMT +1:00

News Source URL: thenextweb.com

Language: English

Article Length: 735 words

Reading Time: 5 minutes read

Sentences: 31 lines

Sentence Length: 24 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © The Next Web

News ID: 25336579

View Article Analysis

About The Next Web

Main Topics: Technology

Official Website: thenextweb.com

Update Frequency: 2 posts per day

Year Established: 2006

Headquarters: Netherlands

News Last Updated: 2 days ago

Coverage Areas: Netherlands

Ownership: Independent Company

Publication Timezone: GMT +1:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #13

Publisher Details

Frequently Asked Questions